Home » Posts tagged with » Taiwan
PharmaEngine, Sentinel Oncology partner to advance SOL-578 Chk1 inhibitor

PharmaEngine, Sentinel Oncology partner to advance SOL-578 Chk1 inhibitor

PharmaEngine has signed a collaboration and license deal with UK-based Sentinel Oncology for advancing the new drug development of SOL-578, a checkpoint kinase 1 inhibitor (Chk1 inhibitor). As per the agreement, the Taiwanese pharma company will finance the investigational new drug (IND) enabling studies for SOL-578. Sentinel Oncology is a drug discovery company engaged in […]

December 6, 2020No CommentRead More

CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial

July 11, 2020 No Comment
CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial

Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial. According to Center Laboratories, the orally administered small molecule drug candidate delivered significant reductions in glycated hemoglobin (HbA1c) in comparison to the placebo group. The phase 2 clinical trial is a […]

Continue reading …

TWi Biotechnology initiates AC-203 phase 2 trial for Epidermolysis Bullosa

October 21, 2018 No Comment
TWi Biotechnology initiates AC-203 phase 2 trial for Epidermolysis Bullosa

TWi Biotechnology, a Taiwanese biotech company, has announced the enrollment of the first patient in a phase 2 trial evaluating AC-203 for the treatment of inherited Epidermolysis Bullosa (EB). The phase 2 trial of AC-203 is a double-blind, intra-individual comparison, proof-of-concept clinical trial and will feature patients as young as two years of age. The […]

Continue reading …